Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?

ESMO gastrointestinal oncology·2026
Same author

CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial.

ESMO open·2025
Same author

Adherence to resistance training and hypocaloric diet among persons near retirement age - A secondary data analysis of three randomized controlled trials.

The journal of nutrition, health & aging·2024
Same author

Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity.

ESMO open·2024
Same author

Alleviating the burden of depression: a simulation study on the impact of mental health services.

Epidemiology and psychiatric sciences·2024
Same author

Prognostic value of deep learning-derived body composition in advanced pancreatic cancer-a retrospective multicenter study.

ESMO open·2024

Related Experiment Video

Updated: Jul 26, 2026

Survivable Stereotaxic Surgery in Rodents
00:08

Survivable Stereotaxic Surgery in Rodents

Published on: October 6, 2008

70.1K

[Imatinib and beyond-what is important for surgery?]

R Hamacher1, J Falkenhorst1, J Treckmann2

  • 1Innere Klinik (Tumorforschung), Sarkomzentrum am Westdeutschen Tumorzentrum, Universitätsklinik Essen, Universität Duisburg-Essen, Hufelandstr. 55, 45122, Essen, Deutschland.

Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|March 24, 2019
PubMed
Summary

Gastrointestinal stromal tumors (GIST) treatment has improved with tyrosine kinase inhibitors (TKI). Novel inhibitors offer new hope for refractory GIST subtypes and advanced cases, potentially changing future treatment strategies.

Keywords:
AdjuvantGastrointestinal stromal tumorMutationNeoadjuvantSurgery

More Related Videos

Endoscopic Cholesteatoma Surgery
08:47

Endoscopic Cholesteatoma Surgery

Published on: January 19, 2022

12.9K
Author Spotlight: Recent Advancements in Reoperative Foregut Surgery
04:14

Author Spotlight: Recent Advancements in Reoperative Foregut Surgery

Published on: September 22, 2023

878

Related Experiment Videos

Last Updated: Jul 26, 2026

Survivable Stereotaxic Surgery in Rodents
00:08

Survivable Stereotaxic Surgery in Rodents

Published on: October 6, 2008

70.1K
Endoscopic Cholesteatoma Surgery
08:47

Endoscopic Cholesteatoma Surgery

Published on: January 19, 2022

12.9K
Author Spotlight: Recent Advancements in Reoperative Foregut Surgery
04:14

Author Spotlight: Recent Advancements in Reoperative Foregut Surgery

Published on: September 22, 2023

878

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastrointestinal Surgery

Background:

  • Gastrointestinal stromal tumors (GIST) treatment has advanced significantly with KIT inhibitors.
  • Surgical resection of primary tumors remains crucial for curative treatment.
  • Tyrosine kinase inhibitors (TKI) show improved long-term tumor control, especially after surgical resection.

Purpose of the Study:

  • To review the evolving treatment landscape for GIST.
  • To highlight the role of molecular predictors and multidisciplinary teams in GIST management.
  • To discuss the impact of novel inhibitors on treatment-refractory GIST subtypes.

Main Methods:

  • Review of current literature on GIST treatment strategies.
  • Analysis of the efficacy of tyrosine kinase inhibitors (TKI) in various GIST settings.
  • Discussion of emerging therapies for specific GIST mutations.

Main Results:

  • Introduction of small molecule KIT inhibitors has dramatically improved GIST treatment.
  • Surgical complete resection enhances the efficacy of TKI in metastatic GIST.
  • Novel potent inhibitors demonstrate efficacy in PDGFR D842V and KIT-mutated GIST, including treatment-refractory cases.

Conclusions:

  • Multimodal treatment approaches for GIST require complex molecular predictors and a deep understanding of GIST biology.
  • Novel inhibitors are poised to significantly alter GIST treatment algorithms.
  • Future GIST management will likely involve personalized therapies based on molecular profiles.